Capricor Therap
CAPR----
Capricor Therap (CAPR)
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treati...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
Capricor Therap Analyst Rating
View MoreForecast & Rating
Jul 23, 2026Price forecast
$53.60170.30%
Forecast & RatingStrong buy
10analysts
- Strong buy80.00%
- Buy20.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- benzinga_article · Jul 9 at 12:35 PM
9 Health Care Stocks With Whale Alerts In Today’s Session
- PUBT · Jun 29 at 08:30 PM
Capricor CFO Anthony Bergmann disposes of USD 732,158 in common shares
- Simplywall · Jun 27 at 06:56 PM
Capricor Therapeutics (CAPR) Is Down 6.8% After Positive Five-Year HOPE-2 DMD Data And FDA Update
- benzinga_article · Jun 26 at 01:06 PM
What's Going On With Capricor Therapeutics Stock On Friday?
- businessinsider · Jun 26 at 09:15 AM
Capricor falls as FDA sets up AdCom meeting to review Duchenne therapy
- PUBT · Jun 26 at 08:05 AM
Capricor says deramiocel meets primary endpoint in HOPE-3 Phase 3 Duchenne muscular dystrophy trial
